Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 9:04 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–21 of 21 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Aliskiren/Amlodipine Clear all
Completed No phase listed Observational

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

NCT04467931
View directory record Official record
Conditions
Hypertension, COVID
Interventions
ACEI/ARB, Non-ACEI/ARB, ACEI, ARB
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
22,213 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Apr 27, 2021 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Aliskiren/Amlodipine/Hydrochlorothiazide (HCTZ) Versus Aliskiren/Amlodipine in US Minority Patients With Stage II Systolic Hypertension

NCT00942994
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Aliskiren/Amlodipine and Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
412 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2009
U.S. locations
5
States / cities
Little Rock, Arkansas • South Miami, Florida • Mattapan, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren HCTZ Compared to HCTZ in Stage 2 Systolic Hypertension in Older Population

NCT00760266
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
55 Years and older
Enrollment
451 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 3, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Combination of Aliskiren+ HCTZ to Irbesartan+ HCTZ or Amlodipine+ HCTZ or HCTZ Alone in Obese Hypertensive Not Responsive to HCTZ 25 mg

NCT00219115
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
493 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 6, 2017 · Synced Sep 24, 2026, 9:04 PM EDT
Terminated Phase 4 Interventional Results available

Study to Evaluate the Efficacy and Safety of the Combination of Valturna and Amlodipine or Valturna and Chlorthalidone Versus Valturna Alone in Patients With Stage 2 Hypertension and Diabetes

NCT01368536
View directory record Official record
Conditions
Hypertension, Stage 2 Hypertension, Diabetes
Interventions
Valturna, Amlodipine, Chlorthalidone, Placebo of Valturna Tablet, Placebo Capsule
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
975 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
95
States / cities
Athens, Alabama • Florence, Alabama • Huntsville, Alabama + 78 more
Source: ClinicalTrials.gov public record
Updated Mar 20, 2013 · Synced Sep 24, 2026, 9:04 PM EDT
Terminated Not applicable Interventional Results available

Assessment of Renin Inhibition on Insulin Sensitivity, Diastolic Function and Aortic Compliance

NCT01252238
View directory record Official record
Conditions
Insulin Sensitivity, Aortic Compliance, Diastolic Function
Interventions
Aliskiren, Valsartan and Aliskiren, Amlodipine
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Feb 12, 2018 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Blood Pressure Lowering of Aliskiren Hydrochlorothiazide (HCTZ) Versus Amlodipine in Stage 2 Hypertension in African Americans

NCT00739596
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren Hydrochlorothiazide (HCTZ): 8 weeks, Amlodipine: 8 weeks
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

A Long Term Safety Study to Test the Combination of Aliskiren/ Amlodipine / Hydrochlorothiazide in Participants With Essential Hypertension

NCT00667719
View directory record Official record
Conditions
Essential Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
564 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jun 6, 2021 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Efficacy and Safety of Aliskiren Administered in Combination With Amlodipine Versus Amlodipine Alone in African American Patients With Stage 2 Hypertension

NCT00853957
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren/Amlodipine, Amlodipine
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
443 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
9
States / cities
Chicago, Illinois • Baltimore, Maryland • Oxon Hill, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 29, 2012 · Synced Sep 24, 2026, 9:04 PM EDT
Withdrawn Phase 4 Interventional

Evaluating the Effect of Aliskiren Versus HCTZ on Coronary Flow Reserve in Hypertensive Type II Diabetics

NCT00994253
View directory record Official record
Conditions
Hypertension, Diabetes Type 2
Interventions
Aliskiren, Hydrochlorothiazide
Drug
Lead sponsor
Corewell Health East
Other
Eligibility
18 Years to 85 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Royal Oak, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 1, 2017 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Aliskiren HCTZ Compared to Amlodipine in Patients With Stage 2 Systolic Hypertension and Diabetes Mellitus

NCT00787605
View directory record Official record
Conditions
Hypertension, Diabetes Mellitus
Interventions
Amlodipine, Hydrochlorothiazide (HCTZ), Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
860 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Oct 26, 2016 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Evaluate the Safety and Efficacy of the Combination of Aliskiren and Amlodipine in Hypertensive Non Responders Patients

NCT00219076
View directory record Official record
Conditions
Hypertension
Interventions
aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
504 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated May 17, 2017 · Synced Sep 24, 2026, 9:04 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

The Study of Novel Dual Renin Angiotensin Aldosterone System (RAAS) Blockade; Valsartan/Aliskiren in African American Patients With Hypertension and the Metabolic Syndrome

NCT01432106
View directory record Official record
Conditions
Hypertension, Metabolic Syndrome
Interventions
Aliskerin/Valsartan and Rampiril
Drug
Lead sponsor
University of Michigan
Other
Eligibility
18 Years to 80 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Nov 17, 2013 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Aliskiren/Amlodipine/Hydrochlorothiazide in Patients With Moderate-severe Hypertension

NCT00765674
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
1,191 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
Denver, Colorado
Source: ClinicalTrials.gov public record
Updated May 8, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional

A Clinical Study to Compare Long-term Efficacy and Safety of an Aliskiren Based Regimen to a Hydrochlorothiazide Based Treatment Regimen With Optional Addition of Amlodipine

NCT00294710
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years to 80 Years
Enrollment
976 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 7, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

A Safety and Efficacy Trial of Aliskiren 150mg , 300 mg Compared to Ramipril 5mg, 10mg in the Elderly

NCT00368277
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Ramipril, Hydrochlorothiazide, Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
901 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Mar 24, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

An Assessment of Long Term Safety of the Combination of Aliskiren / Amlodipine in Patients With High Blood Pressure

NCT00402103
View directory record Official record
Conditions
Hypertension
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
556 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Santa Fe, New Mexico
Source: ClinicalTrials.gov public record
Updated Mar 9, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 2 Interventional Results available

Comparison of Aliskiren and Amlodipine on Insulin Resistance and Endothelial Dysfunction in Patients With Hypertension and Metabolic Syndrome

NCT00417170
View directory record Official record
Conditions
High Blood Pressure, Metabolic Syndrome, Insulin Resistance, Endothelial Dysfunction
Interventions
Aliskiren, Amlodipine, Placebo Aliskiren, Placebo Amlodipine
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Santa Monica, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Terminated Phase 3 Interventional Results available

A Randomized Controlled Trial of Aliskiren in the Prevention of Major Cardiovascular Events in Elderly People

NCT01259297
View directory record Official record
Conditions
Cardiovascular Events
Interventions
Aliskiren, Amlodipine, Hydrochlorothiazide (HCTZ), Placebo for Aliskiren, Placebo for Amlodipine, Placebo for Hydrochlorothiazide (HCTZ)
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
65 Years and older
Enrollment
2,336 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
14
States / cities
Birmingham, Alabama • Los Angeles, California • Northridge, California + 11 more
Source: ClinicalTrials.gov public record
Updated Apr 7, 2014 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy and Safety of Aliskiren Alone and in Combination With Amlodipine in Essential Hypertension

NCT00739973
View directory record Official record
Conditions
Hypertension
Interventions
Placebo, Aliskiren 150 mg tablet, Aliskiren 300 mg tablet, Amlodipine 5 mg capsule, Amlodipine 10 mg capsule, Aliskiren/amlodipine 150/5 mg tablet, Aliskiren/amlodipine 150/10 mg tablet, Aliskiren/amlodipine 300/5 mg tablet, Aliskiren/amlodipine 300/10 mg tablet
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,694 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 5, 2011 · Synced Sep 24, 2026, 9:04 PM EDT
Completed Phase 4 Interventional Results available

Direct Renin Inhibition Effects on Atherosclerotic Biomarkers

NCT00818779
View directory record Official record
Conditions
Coronary Artery Disease, Type 2 Diabetes Mellitus
Interventions
Aliskiren, Amlodipine
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 85 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Lubbock, Texas
Source: ClinicalTrials.gov public record
Updated Dec 4, 2017 · Synced Sep 24, 2026, 9:04 PM EDT